McDonald Partners’s Coherus Oncology CHRS Stock Holding History

McDonald Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22	Closed	-$351	–	380
2021 Q4	$351	Buy	+22	New	+$385	﹤0.01%	523

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

McDonald Partners's CHRS Position: Q1 2022 in Review

McDonald Partners sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 22 shares — an estimated $351 sold.

McDonald Partners first reported a position in CHRS in Q4 2021 and held it in 1 quarter. The position peaked at $351 in Q4 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

McDonald Partners reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
McDonald Partners sold 22 Coherus Oncology shares in Q1 2022, an estimated $351.
McDonald Partners first reported a position in Coherus Oncology in Q4 2021 and held it in 1 quarter.
McDonald Partners's Coherus Oncology position peaked at $351 in Q4 2021.
183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on McDonald Partners's 13F filing for Q1 2022, filed 29 Apr 2022.